REFERENCES
Adhanom Ghebreyesus, T (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19.
Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. (2015). Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann Rheum Dis 74:1037–44.
Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, et al. (2020). Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun 109:102442.
Chen N, Zhou M, Dong X, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507‐513.
Chiu Y-M, Chen D-Y (2020). Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 16:207–28
Dong E, Du H, Gardner L (2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 3099:19–20.
Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. (2020). Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. DOI:10.1016/S0140-6736(20)30858-8.
Fu B, Xu X, Wei H (2020). Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 18:164.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. (2020). Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med. DOI:10.1056/NEJMc2009567.
Honkila M, Niinimäki R, Taskinen M, Kuismin O, Kettunen K, Saarela J, et al. (2019). A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature. BMC Infect Dis 19:404.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.
Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP (2004). Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63:1056‐1061.
Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020). Articles Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 6736(20):1–10.
Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et al. (2014). The natural history of influenza infection in the severely immunocompromised vs non immunocompromised hosts. Clin Infect Dis 58:214-24.
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9:757–60.
Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. (2020). Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 50:564–70.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. (2020). Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. Eurosurveillance. [Online] Available fromhttps://www.eurosurveillance.org/content/10.2807/1560- 7917.ES.2020.25.10.2000180 [Accessed 18th April 2020].
Nasuno M, Miyakawa M, Tanaka H, Motoya S (2017). Short-and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study. Digestion 95:67–71.
Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, et al. (2020). Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 94:154-155.
Ruiz-Irastorza G, Danza A, Khamashta M (2012). Glucocorticoid use and abuse in SLE. Rheumatol 51:1145–53.
Sawalha AH, Zhao M, Coit P, Lu Q (2020). Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 215:108410.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. (2020). Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. DOI:10.1101/2020.04.10.
Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. (2012). Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 Year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379:1712–20.
Vom Steeg LG, Klein SL (2019). Sex and sex steroids impact influenza pathogenesis across the life course. Semin Immunopathol 41:189–194.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061–1069.
Wu Z, Mc Googan JM. (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239-1242.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. DOI:10.1073/pnas.20056151171.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clin Immunol 214:108393.
Zhong J, Tang J, Ye C, Dong L (2020) The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. DOI:10.1016/S2665-9913(20)30120-X.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062. Erratum in: Lancet 395:1038.